Earvin Liang

Dr. Earvin Liang is a clinical pharmacology and clinical development expert in CNS, with a specialty in Alzheimer’s disease, neuropsychiatric, and neurodegenerative indications. Dr. Liang brings over 20 years of industry experience ranging from pre-clinical drug identification and optimization, clinical pharmacology programs, Phase 2 studies, to late-stage global clinical trials. Dr. Liang has extensive clinical experience in passive and active amyloid immunotherapy for Alzheimer’s disease, cognition in Down syndrome, neuropsychiatric indications in dementia, Parkinson’s disease, and dementia-related psychosis, as well as several early-stage programs with gamma-secretase inhibitors.

Dr. Liang was most recently an independent clinical pharmacology and development consultant to several biotechnology companies. Prior to that, he spent 8 years as a key member supporting clinical development of bapineuzumab (anti-amyloid antibody), ACC-001 (amyloid vaccine), ELND005 (amyloid anti-oligomer agent), and multiple sclerosis immune-modulation programs at Elan Pharmaceuticals, Janssen Alzheimer Immunotherapy, and Transition Therapeutics.

Dr. Liang holds a Ph.D. in Pharmaceutical Sciences from the University of Florida and a BS in Pharmacy from Taipei Medical University. He is a licensed pharmacist and has authored more than 50 peer-reviewed papers and abstracts, and given over 130 oral and poster presentations at international conferences and symposia.